RESUMEN
BACKGROUND: This study aimed to report the outcomes of the immediate loading of implants with fixed rehabilitations in edentulous geriatric patients. METHODS: Edentulous geriatric patients were diagnosed with an oral examination, radiographic evaluation, and intermaxillary relations and treated with fixed rehabilitation over several implants. After immediate surgery, the implants were immediately loaded with a fully fixed prosthesis. RESULTS: Twenty-four patients (20 females and 4 males) were treated using a total 210 implants. All patients (100%) had a previous history of periodontitis. Eleven patients (45.8%) were smokers. Eleven patients (45.8%) suffered from chronic medical diseases (i.e., diabetes, cardiovascular diseases). The study's clinical follow-up period extended for three years, during which thirty-three fixed prostheses were installed over the implants in 24 patients. The average marginal bone loss measured was 1.33 ± 0.17 mm. The success rate of the implants and prosthodontics being placed in this study yielded 98.5% and 97%, respectively. One patient (4.2%) showed some kind of technical complications. Eleven patients (45.8%) showed mucositis, and 25 implants (11.9%) in 10 patients (41.7%) were associated with peri-implantitis. CONCLUSIONS: This study shows that the treatment of edentulous geriatric patients by immediate loading of implants with fixed rehabilitations is a clinically successful protocol but with a high prevalence of peri-implant diseases.
RESUMEN
BACKGROUND: The self-report Psychiatric Diagnostic Screening Questionnaire PDSQ is designed to screen Axis I psychiatric disorders. We aim to determine its psychometric properties in Spanish outpatients and assess its relationship with two interviews (for psychopathology and for personality disorders) and clinical/demographic variables. METHODOLOGY: We administered the study questionnaire, the Mini International Neuropsychiatric Interview Plus (MINI-Plus), the Standardised Assessment of Personality Abbreviated Scale (SAPAS), and the List of Threatening Experiences Questionnaire (LTE-Q) to 375 patients at two public outpatient centres. Reliability of the study questionnaire was evaluated (Cronbach's alpha, ?) and known-group validity measured by comparing groups based on demographic and clinical variables (binary logistic regression analysis) and MINI-Plus diagnoses (Mann-Whitney U). The diagnostic accuracy of the study questionnaire score was analysed taking the MINI-Plus diagnoses as the gold standard (ROC analysis). RESULTS: Internal consistency was adequate across all PDSQ scales (? >0.7; mean ?=0.85). Known-group comparisons were satisfactory. Female and male patients showed higher prevalence of internalizing and externalizing diagnoses, respectively. Younger age, more life events and limitations, higher SAPAS scores, and lower economic levels were linked to a greater number of PDSQ diagnoses. Inter-group differences were found for all PDSQ scales based on the corresponding MINI-Plus diagnoses. Mean values of sensitivity, AUC, and negative predictive value were 88.7, 0.82, and 96.7, respectively. CONCLUSIONS: When applied to a sample of Spanish outpatients, the PDSQ exhibits satisfactory psychometric properties and adequate relationships with the psychopathology and personality interviews, and clinical and demographic variables. The study questionnaire is suitable for assessing comorbidity and psychopathology dimensions.
Asunto(s)
Trastornos Mentales , Humanos , Femenino , Masculino , España/epidemiología , Psicometría , Reproducibilidad de los Resultados , Trastornos Mentales/diagnóstico , Trastornos Mentales/epidemiología , Instituciones de Atención AmbulatoriaRESUMEN
Backgroun: The selfreport Psychiatric Diagnostic Screening Questionnaire PDSQ is designed to screen Axis I psychiatric disorders. We aim to determine its psychometric properties in Spanish outpatients and assess its relationship with two interviews (for psychopathology and for personality disorders) and clinical/demographic variables. Methodology: We administered the study questionnaire, the Mini International Neuropsychiatric Interview Plus (MINIPlus), the Standardised Assessment of Personality Abbreviated Scale (SAPAS), and the List of Threatening Experiences Questionnaire (LTEQ) to 375 patients at two public outpatient centres. Reliability of the study questionnaire was evaluated (Cronbachs alpha, a) and knowngroup validity measured by comparing groups based on demographic and clinical variables (binary logistic regression analysis) and MINIPlus diagnoses (MannWhitney U). The diagnostic accuracy of the study questionnaire score was analysed taking the MINIPlus diagnoses as the gold standard (ROC analysis). Results: Internal consistency was adequate across all PDSQ scales (a>0.7; mean a=0.85). Knowngroup comparisons were satisfactory. Female and male patients showed higher prevalence of internalizing and externalizing diagnoses, respectively. Younger age, more life events and limitations, higher SAPAS scores, and lower economic levels were linked to a greater number of PDSQ diagnoses. Intergroup differences were found for all PDSQ scales based on the corresponding MINIPlus diagnoses. Mean values of sensitivity, AUC, and negative predictive value were 88.7, 0.82, and 96.7, respectively. Conclusions: When applied to a sample of Spanish outpatients, the PDSQ exhibits satisfactory psychometric properties and adequate relationships with the psychopathology and personality interviews, and clinical and demographic variables. The study questionnaire is suitable for assessing comorbidity and psychopathology dimensions.(AU)
Fundamento: El PDSQ (Psychiatric Diagnostic Screening Questionnaire) es un cuestionario autoadministrado para el cribado de diagnósticos psiquiátricos del eje I. El objetivo es estudiar sus propiedades psicométricas en pacientes ambulatorios españoles y analizar su relación con dos entrevistas (de psicopatología y de trastornos de personalidad), y con variables clínicas y demográficas. Material y métodos: Se administraron los instrumentos PDSQ, MINIPlus, SAPAS, y LTE-Q a 375 pacientes en dos centros ambulatorios públicos. Se estudió la fiabilidad del PDSQ (α de Cronbach). La validez de grupos conocidos se analizó comparando subgrupos organizados por variables demográficas y clínicas (regresión logística binaria) y por diagnósticos MINI Plus (U de Mann-Whitney). Se estudió el desempeño diagnóstico del PDSQ considerando los diagnósticos MINI Plus como gold standard (análisis ROC). Resultados: La consistencia interna del PDSQ fue adecuada en todas las escalas (α >0,7; media=0,85). Las comparaciones entre grupos conocidos fueron satisfactorias. Mujeres y hombres mostraron prevalencias mayores de trastornos internalizantes y externalizantes, respectivamente. Una menor edad, más sucesos vitales y limitaciones, puntuaciones mayores en SAPAS y niveles económicos más bajos se relacionaron con mayor número de diagnósticos PDSQ. Los grupos basados en los correspondientes diagnósticos MINIPlus difirieron en todas las escalas del PDSQ. Los valores medios de sensibilidad, AUC y valor predictivo negativo fueron 88,7; 0,82 y 96,7, respectivamente. Conclusiones: En su aplicación a pacientes españoles ambulatorios, el PDSQ muestra, propiedades psicométricas satisfactorias y relaciones adecuadas con entrevistas de psicopatología y personalidad, así como con variables clínicas y demográficas. El PDSQ es adecuado para evaluar comorbilidad y dimensiones de psicopatología.(AU)
Asunto(s)
Humanos , Masculino , Femenino , Psicometría , Trastornos Mentales/diagnóstico , Reproducibilidad de los Resultados , Psicopatología/instrumentación , Pruebas Psicológicas , Sistemas de Salud , Encuestas y Cuestionarios , PsiquiatríaRESUMEN
Background and objectives: Common mental disorders (CMDs) in mental health settings show high rates of comorbidities. While semi-structured interviews are the gold standard to establish a diagnosis, there are self-report instruments such as the Psychiatric Diagnostic Screening Questionnaire (PDSQ) that aids clinicians in improving the diagnostic process in a time-efficient manner.MethodsNetwork analysis of the 13 domains of the PDSQ was applied to a sample of 374 first-contact outpatients to identify domains of psychopathology acting as hubs and bridges of interconnections within the CMDs.ResultsA global network densely connected with positive connections among PDSQ domains was found. The global network has four main clusters: depression-anxiety, somatoform, psychosis and substance-related domains. This network allowed for the identification of main nodes acting as hubs favoring interconnections between dimensions and main bridges easing the connections between clusters.ConclusionThe network structure of the PDSQ domains might provide a complementary explanation to the high rates of comorbidity among CMDs. Moreover, our results support the relevance of the self-administered PDSQ inventory to account for a deeper understanding of comorbidities among CMDs. (AU)
Asunto(s)
Humanos , Salud Mental , Comorbilidad , Trastornos Mentales , Psicopatología , Esquizofrenia , DiagnósticoRESUMEN
Mycobacterium abscessus (MABS) is the most pathogenic and drug-resistant rapidly growing mycobacteria. However, studies on MABS epidemiology, especially those focusing on subspecies level, are scarce. We aimed to determine MABS subspecies distribution and its correlation with phenotypic and genotypic antibiotic profiles. A retrospective multicenter study of 96 clinical MABS isolates in Madrid between 2016 to 2021 was conducted. Identification at the subspecies level and resistance to macrolides and aminoglycosides were performed by the GenoType NTM-DR assay. The MICs of 11 antimicrobials tested against MABS isolates were determined using the broth microdilution method (RAPMYCOI Sensititer titration plates). Clinical isolates included 50 (52.1%) MABS subsp. abscessus; 33 (34.4%) MABS subsp. massiliense; and 13 (13.5%) MABS subsp. bolletii. The lowest resistance rates corresponded to amikacin (2.1%), linezolid (6.3%), cefoxitin (7.3%), and imipenem (14.6%), and the highest to doxycycline (100.0%), ciprofloxacin (89.6%), moxifloxacin (82.3%), cotrimoxazole (82.3%), tobramycin (81.3%), and clarithromycin (50.0% at day 14 of incubation). Regarding tigecycline, although there are no susceptibility breakpoints, all strains but one showed MICs ≤ 1 µg/mL. Four isolates harbored mutations at positions 2058/9 of the rrl gene, one strain harbored a mutation at position 1408 of the rrl gene, and 18/50 harbored the T28C substitution at erm(41) gene. Agreement of the GenoType results with clarithromycin and amikacin susceptibility testing was 99.0% (95/96). The rate of MABS isolates showed an upward trend during the study period, being M. abscessus subsp. abscessus the most frequently isolated subspecies. Amikacin, cefoxitin, linezolid, and imipenem showed great in vitro activity. The GenoType NTM-DR assay provides a reliable and complementary tool to broth microdilution for drug resistance detection. IMPORTANCE Infections caused by Mycobacterium abscessus (MABS) are increasingly being reported worldwide. Identifying MABS subspecies and assessing their phenotypic resistance profiles are crucial for optimal management and better patient outcomes. M. abscessus subspecies differ in erm(41) gene functionality, which is a critical determinant of macrolide resistance. Additionally, resistance profiles of MABS and the subspecies distribution can vary geographically, highlighting the importance of understanding local epidemiology and resistance patterns. This study provides valuable insights into the epidemiology and resistance patterns of MABS and its subspecies in Madrid. Elevated resistance rates were observed for several recommended antimicrobials, emphasizing the need for cautious drug use. Furthermore, we assessed the GenoType NTM-DR assay, which examines principal mutations in macrolides and aminoglycosides resistance-related genes. We observed a high level of agreement between the GenoType NTM-DR assay and the microdilution method, indicating its usefulness as an initial tool for early initiation of appropriate therapy.
Asunto(s)
Infecciones por Mycobacterium no Tuberculosas , Mycobacterium abscessus , Humanos , Antibacterianos/farmacología , Claritromicina , Amicacina/farmacología , Linezolid , Cefoxitina , España/epidemiología , Infecciones por Mycobacterium no Tuberculosas/epidemiología , Infecciones por Mycobacterium no Tuberculosas/microbiología , Macrólidos , Farmacorresistencia Bacteriana/genética , Imipenem , Aminoglicósidos , Pruebas de Sensibilidad MicrobianaRESUMEN
Nontuberculous mycobacteria (NTM) are gaining interest with the increased number of infected patients. NTM Elite agar is designed specifically for the isolation of NTM without the decontamination step. We assessed the clinical performance of this medium combined with Vitek mass spectrometry (MS) matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) technology for the isolation and identification of NTM in a prospective multicenter study, including 15 laboratories (24 hospitals). A total of 2,567 samples from patients with suspected NTM infection were analyzed (1,782 sputa, 434 bronchial aspirates, 200 bronchoalveolar lavage samples, 34 bronchial lavage samples, and 117 other samples). A total of 220 samples (8.6%) were positive with existing laboratory methods against 330 with NTM Elite agar (12.8%). Using the combination of both methods, 437 isolates of NTM were detected in 400 positive samples (15.6% of samples). In total, 140 samples of the standard procedures (SP) and 98 of the NTM Elite agar were contaminated. NTM Elite agar showed a higher performance for rapidly growing mycobacteria (RGM) species than SP (7% versus 3%, P < 0.001). A trend has been noted for the Mycobacterium avium complex (4% with SP versus 3% with NTM Elite agar, P = 0.06). The time to positivity was similar (P = 0.13) between groups. However, the time to positivity was significantly shorter for the RGM in subgroup analysis (7 days with NTM and 6 days with SP, P = 0.01). NTM Elite agar has been shown to be useful for the recovery of NTM species, especially for the RGM. Using NTM Elite agar + Vitek MS system in combination with SP increases the number of NTM isolated from clinical samples.
Asunto(s)
Infecciones por Mycobacterium no Tuberculosas , Mycobacterium , Humanos , Micobacterias no Tuberculosas , Agar , Estudios Prospectivos , Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Infecciones por Mycobacterium no Tuberculosas/microbiología , Complejo Mycobacterium avium , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodosRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Anciano , Infecciones por Corynebacterium/etiología , Infecciones del Sistema Respiratorio/complicaciones , Complicaciones de la Diabetes , Corynebacterium diphtheriae/aislamiento & purificación , Infecciones por Corynebacterium/diagnóstico , Infecciones por Corynebacterium/microbiología , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Antibacterianos/uso terapéutico , Eritromicina/uso terapéuticoRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Anciano , Bacteriemia/complicaciones , Infecciones por Clostridium/complicaciones , Infecciones del Sistema Respiratorio/diagnóstico , Infecciones por Clostridium/diagnóstico , Infecciones por Clostridium/microbiología , Clostridium/aislamiento & purificación , Asma/complicaciones , Cultivo de Sangre/métodosRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Enfermedad Relacionada con los Viajes , Diarrea/diagnóstico , Vibrio cholerae/aislamiento & purificación , Diarrea/microbiología , Vibrio cholerae/efectos de los fármacosAsunto(s)
Asma/complicaciones , Bacteriemia/diagnóstico , Infecciones por Clostridium/diagnóstico , Clostridium/aislamiento & purificación , Errores Diagnósticos , Infecciones del Sistema Respiratorio/diagnóstico , Anciano , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Bacteriemia/microbiología , Cefotaxima/uso terapéutico , Infecciones por Clostridium/tratamiento farmacológico , Infecciones por Clostridium/microbiología , Quimioterapia Combinada , Femenino , Humanos , Inmunocompetencia , Levofloxacino/uso terapéuticoRESUMEN
BACKGROUND: Our study focuses on the role that human Cytomegalovirus (CMV) genotypes play in the development of disease. OBJECTIVES: (1) To analyze the frequency of various genotype envelope proteins (gB, gH) in a group of solid organ transplant (SOT) recipients; (2) to assess their correlation with CMV disease; (3) to study the association between any of the genotypes and viral loads. STUDY DESIGN: A retrospective observational study conducted by analyzing CMV gB and gH genotypes detected with real-time polymerase chain reaction (PCR)-specific assays in 162 CMV-positive blood samples from 62 SOT recipients. Demographic, clinical, and microbiological data were recorded. RESULTS: Mixed gB genotypes were associated with viral syndrome (70%, p = .004), earlier presentation of symptoms (48.27 ± 27.03 versus 74.33 ± 47.25 days, respectively, p = .001), and higher median of the plasma viral load log10 (UI/ml) than infection with a single genotype (p = .004). Furthermore, the gB3 genotype was detected more frequently in patients who presented with asymptomatic viremia (77.27%, p < .0001). The gH1 genotype was more frequent (65%) in patients who presented with asymptomatic viremia (p = .003), and it caused infection later than gH2 or the mixed genotype (84.88 ± 48.10 versus 57.91 ± 39.18 days, respectively, p < .001). CONCLUSIONS: Patients who presented mixed gB genotypes more frequently developed clinical manifestations and earlier, higher, plasma viral loads. The detection of gB and gH genotypes by real-time PCR can provide relevant information to stratify the risk of SOT recipients to develop symptomatic infection by CMV.
Asunto(s)
Infecciones por Citomegalovirus/virología , Citomegalovirus/genética , Receptores de Trasplantes , Proteínas del Envoltorio Viral/genética , Adulto , Citomegalovirus/clasificación , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/complicaciones , ADN Viral/sangre , ADN Viral/genética , Femenino , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Reacción en Cadena en Tiempo Real de la Polimerasa , Estudios Retrospectivos , Análisis de Secuencia de ADN , Carga ViralRESUMEN
OBJETIVO: Estimar la prevalencia de infección por el virus de la hepatitis C (VHC) en Navarra, distinguiendo entre infecciones diagnosticadas y no diagnosticadas. MÉTODOS: Se estudiaron pacientes con cirugía programada no relacionada con la infección por VHC, a los que se les realizó de forma sistemática la determinación de anticuerpos del VHC entre enero de 2014 y septiembre de 2016. En los pacientes con enzimoinmunoanálisis positivo se confirmó el diagnóstico mediante inmunoblot y/o determinación de ARN-VHC. También se comprobó la existencia de resultados positivos previos. La prevalencia se estandarizó por sexo y edad a la población de Navarra. RESULTADOS: Se analizaron 7.378 pacientes, 50% mujeres, con una mediana de edad de 46 años. En 69 se detectaron anticuerpos del VHC, lo que supone una prevalencia poblacional estimada de 0,83% (intervalo de confianza del 95%: 0,64-1,05), mayor en hombres (1,11%) que en mujeres (0,56%; p = 0,0102). Entre los que resultaron anti-VHC positivos, 67 (97%) habían tenido alguna prueba positiva previa. La prevalencia poblacional de diagnóstico previo de anti-VHC fue del 0,80%, y la de nuevos diagnósticos, del 0,03%. El 78% de los pacientes con anti-VHC positivo habían presentado alguna determinación de ARN-VHC detectable. Se estima que el 0,65% de la población había tenido ARN-VHC detectable y el 0,51% lo seguía teniendo en el momento del estudio. CONCLUSIÓN: Estos resultados revisan a la baja las estimaciones previas de prevalencia de infección por VHC. Una proporción mínima de las personas con anti-VHC permanecen sin diagnosticar, y solo una parte mantienen infección activa
OBJECTIVE: To estimate the prevalence of hepatitis C virus (HCV) infection in Navarra, Spain, as well as to distinguish between diagnosed and undiagnosed infections. METHODS: A study was conducted on patients scheduled for surgery unrelated to HCV infection. They were all tested for HCV antibodies, under a routine scheme, from January 2014 to September 2016. Patients with a positive result by enzyme immunoassay were confirmed using immunoblot and/or HCV-RNA. Previous laboratory results were also taken into account. The prevalence was adjusted to the sex and age structure of the Navarra population. RESULTS: The study included a total of 7,378 patients with a median age 46 years, of whom 50% women. HCV antibodies were detected in 69 patients, which is a prevalence in the population of 0.83% (95% confidence interval: 0.64-1.05), and was higher in men (1.11%) than in women (0.56%; P = .0102). Among the HCV positive patients, 67 (97%) had had another previous positive result. Population prevalence of previous positive HCV was 0.80%, and was 0.03% for a new diagnosis. Of the HCV positive patients, 78% had detectable HCV-RNA. It was estimated that 0.65% of the population had had detectable HCV-RNA, and 0.51% continued to have it when recruited into the study. CONCLUSION: Previous estimates of prevalence of HCV infection should be revised downwards. Only a small proportion of HCV positive patients remain undiagnosed, and only a small part have active infection
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Lactante , Preescolar , Niño , Adolescente , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Hepatitis C/epidemiología , Hepatitis C/diagnóstico , Anticuerpos contra la Hepatitis C/sangre , Hepacivirus/inmunología , Prevalencia , España/epidemiología , Técnicas para InmunoenzimasAsunto(s)
Infecciones por Escherichia coli/transmisión , Escherichia coli/efectos de los fármacos , beta-Lactamasas/genética , Anciano , Anciano de 80 o más Años , Técnicas de Tipificación Bacteriana , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple/genética , Escherichia coli/genética , Escherichia coli/patogenicidad , Infecciones por Escherichia coli/microbiología , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Tipificación de Secuencias MultilocusRESUMEN
OBJECTIVE: To estimate the prevalence of hepatitis C virus (HCV) infection in Navarra, Spain, as well as to distinguish between diagnosed and undiagnosed infections. METHODS: A study was conducted on patients scheduled for surgery unrelated to HCV infection. They were all tested for HCV antibodies, under a routine scheme, from January 2014 to September 2016. Patients with a positive result by enzyme immunoassay were confirmed using immunoblot and/or HCV-RNA. Previous laboratory results were also taken into account. The prevalence was adjusted to the sex and age structure of the Navarra population. RESULTS: The study included a total of 7,378 patients with a median age 46 years, of whom 50% women. HCV antibodies were detected in 69 patients, which is a prevalence in the population of 0.83% (95% confidence interval: 0.64-1.05), and was higher in men (1.11%) than in women (0.56%; P=.0102). Among the HCV positive patients, 67 (97%) had had another previous positive result. Population prevalence of previous positive HCV was 0.80%, and was 0.03% for a new diagnosis. Of the HCV positive patients, 78% had detectable HCV-RNA. It was estimated that 0.65% of the population had had detectable HCV-RNA, and 0.51% continued to have it when recruited into the study. CONCLUSION: Previous estimates of prevalence of HCV infection should be revised downwards. Only a small proportion of HCV positive patients remain undiagnosed, and only a small part have active infection.
Asunto(s)
Hepatitis C/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Estudios Transversales , Grupos Diagnósticos Relacionados , Femenino , Hepatitis C/diagnóstico , Anticuerpos contra la Hepatitis C/sangre , Humanos , Lactante , Masculino , Persona de Mediana Edad , Cuidados Preoperatorios , Prevalencia , ARN Viral/sangre , Estudios Seroepidemiológicos , España/epidemiología , Carga Viral , Adulto JovenRESUMEN
Background: The 2009 pandemic influenza A(H1N1) (A[H1N1]pdm09) vaccine component has remained unchanged from 2009. We estimate the effectiveness of current and prior inactivated influenza A(H1N1)pdm09 vaccination from influenza seasons 2010-2011 to 2015-2016. Methods: Patients attended with influenza-like illness were tested for influenza. Four periods with continued A(H1N1)pdm09 circulation were included in a test-negative design. Results: We enrolled 1278 cases and 2343 controls. As compared to individuals never vaccinated against influenza A(H1N1)pdm09, the highest effectiveness (66%; 95% confidence interval, 49%-78%) was observed in those vaccinated in the current season who had received 1-2 prior doses. The effectiveness was not statistically lower in individuals vaccinated in the current season only (52%) or in those without current vaccination and >2 prior doses (47%). However, the protection was lower in individuals vaccinated in the current season after >2 prior doses (38%; P = .009) or those currently unvaccinated with 1-2 prior doses (10%; P < .001). Current-season vaccination improved the effect in individuals with 1-2 prior doses and did not modify significantly the risk of influenza in individuals with >2 prior doses. Conclusion: Current vaccination or several prior doses were needed for high protection. Despite the decreasing effect of repeated vaccination, current-season vaccination was not inferior to no current-season vaccination.
Asunto(s)
Vacunas contra la Influenza/administración & dosificación , Vacunas contra la Influenza/uso terapéutico , Gripe Humana/epidemiología , Gripe Humana/prevención & control , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Humanos , Subtipo H1N1 del Virus de la Influenza A , Modelos Logísticos , Masculino , Persona de Mediana Edad , España , Vacunación , Adulto JovenRESUMEN
In 2014, an autochthonous case of introduced malaria caused by Plasmodium vivax was identified in Spain. The strain that infected this patient was identical to that of a prior imported case from Pakistan. This is the first case where the source of infection could be identified since elimination in Spain.
Asunto(s)
Malaria Vivax , Plasmodium vivax , Humanos , Malaria Vivax/diagnóstico , Malaria Vivax/parasitología , Malaria Vivax/transmisión , Masculino , Persona de Mediana Edad , Pakistán , España , ViajeRESUMEN
INTRODUCTION: Diagnosis of HSV-1 keratitis (HK) is frequently based on clinical findings. Invasive specimens (corneal scrapings, biopsies) are required for microbiological diagnosis. Methods Corneal scrapings and conjunctival swabs were collected on patients with/without clinical suspicion of HK from 2007 to 2012.ResultsThe sensitivity, specificity, positive and negative predictive values for conjunctival swabs by PCR was 77.8, 92.1, 84.4 and 88.3, respectively. Discussion Conjunctival swabs by PCR may help in the diagnosis of HK, despite the limited sensitivity
INTRODUCCIÓN: El diagnóstico de queratitis herpética (QH) está basado normalmente en hallazgos clínicos. Para el diagnóstico microbiológico se requieren muestras invasivas (raspado corneal, biopsias).MÉTODOS: Raspados corneales y exudados conjuntivales fueron obtenidos de pacientes con/sin sospecha clínica de QH del ano 2007 al 2012.RESULTADOS: La sensibilidad, la especificidad y los valores predictivos positivos y negativos para la PCR enexudados conjuntivales fueron 77,8, 92,1, 84,4 y 88,3, respectivamente. DISCUSIÓN: La PCR en exudados conjuntivales puede ayudar en el diagnóstico, a pesar de su limitada sensibilidad